Ser244
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser244  -  E2F4 (human)

Site Information
QEASRPNsPQLTPTA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 28843800

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 ) , mutation of modification site ( 2 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , colon ( 2 ) , epithelial ( 2 ) , HEK293T (epithelial) ( 2 ) , intestinal ( 2 )

Upstream Regulation
Putative in vivo kinases:
ERK1 (human) ( 2 )
Kinases, in vitro:
ERK1 (human) ( 2 )
Treatments:
EGF ( 2 ) , LPA ( 2 ) , SB216763 ( 2 ) , serum ( 2 ) , U0126 ( 2 )

Downstream Regulation
Effects of modification on E2F4:
intracellular localization ( 2 )
Effects of modification on biological processes:
cell cycle regulation ( 2 ) , transcription, induced ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:
colorectal cancer ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Paquin MC, et al. (2013) ERK-associated changes in E2F4 phosphorylation, localization and transcriptional activity during mitogenic stimulation in human intestinal epithelial crypt cells. BMC Cell Biol 14, 33
23919615   Curated Info